IACS Leadership
Associate Director, Mouse Cancer Models
James Horner, B.S.
Together with Ronald DePinho, M.D., James Horner, B.S. and his facility staff have a long record of mouse engineering and phenotypic characterization of cancer-prone strains. More than 20 years ago, they established the first National Cancer Institute-supported shared transgenic and gene targeting facility at the Albert Einstein College of Medicine. Using early technologies, they generated more than 2,000 different transgenic mouse strains and approximately 200 germline mutant strains for more than 55 different laboratories.
At the Dana-Farber Cancer Institute, this effort was continued with the production of many hundreds of germline transgenic and knock-out/knock-in alleles, the design of which are, on average, far more complex than early generation alleles in the 1990s.
Institute Leadership
- Giulio Draetta, M.D., Ph.D. - Director
- Lynda Chin, M.D. - Scientific Director
- Carlo Toniatti, M.D., Ph.D. - Head of Research
- Philip Jones, Ph.D. - Head of Drug Discovery
- Eric Devroe, Ph.D. - Executive Director, Strategic Alliances
- Jannik Andersen, Ph.D. - Senior Associate Director, Drug Discovery Biology
- Joseph Marszalek, Ph.D. - Senior Associate Director, Target Validation
- Timothy Heffernan, Ph.D. - Associate Director, Target Discovery
- James Horner, B.S. - Associate Director, Mouse Cancer Models
- Ming-Kuei Jang, Ph.D., - Associate Director, Neurobiology
- Alexei Protopopov, Ph.D. - Associate Director, Oncogenomics
- Jianhua (John) Zhang, Ph.D. - Associate Director, Bioinformatics